Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupPlasma cell neoplasmsTransplantationDiseaseMultiple MyelomaStem Cell mobilizationSubgroupICD10C90.-C90.0-MeSHHematopoietic Stem Cell MobilizationMultiple MyelomaPlasmacytomaSequenceChemotherapyChemo-substanceCyclophosphamideChemo-substanceCyclophosphamideChemo-substanceCyclophosphamideChemo-substanceCyclophosphamideNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimFosaprepitantFurosemideGranisetronMesnaPlerixaforSupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimFosaprepitantFurosemideGranisetronMesnaPlerixaforSupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimFosaprepitantFurosemideGranisetronMesnaPlerixaforSupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimFosaprepitantFurosemideGranisetronMesnaPlerixaforNo. Substances8Protocol classificationTherapy classificationstudy analogIntensityhigh doseTherapy indicationFirst lineTherapy phaseconditioningTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorGoldschmidt HDiseaseMM Stadium II und III, 18 - 65 Jahre, ECOG 0-3 (3 nur wenn durch Myelom bedingt), ErstlinieOriginHOVON-65/GMMG-HD4 StudieProtocols in Revision 1 protocol foundProtocols under revision.High dose Cyclophosphamide 2000 for stem cell mobilization, Multiple Myeloma (PID535 V1.0.1)
